| Enzo Biochem (ENZ) | |||
|---|---|---|---|
| 2.17 0.04 (1.88%) | 03-24 16:00 | ||
| Open: | 2.12 | Pre. Close: | 2.13 |
| High: | 2.22 | Low: | 2.115 |
| Volume: | 561,066 | Market Cap: | 108(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 2.87 One year: 3.36 |
| Support: | Support1: 1.56 Support2:  |
| Resistance: | Resistance1: 2.46 Resistance2: 2.87 |
| Pivot: | 1.54 |
| Moving Averages: | MA(5): 2.13  MA(20): 1.44 MA(100): 1.59 MA(250): 2.08 |
| MACD: | MACD(12,26): 0.22 Signal(12,26,9): 0.11 |
| %K %D: | %K(14,3): 76.48 %D(3): 75.34 |
| RSI: | RSI(14): 73.22 |
| 52-Week: | High: 3.06 Low: 1 Change(%): -26.2 |
| Average Vol(K): | 3-Month: 782 10-Days: 4362 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 2.233 - 2.242 | 2.242 - 2.252 |
| Low: | 2.089 - 2.098 | 2.098 - 2.107 |
| Close: | 2.155 - 2.171 | 2.171 - 2.187 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ENZ ] has closed below upper band by 18.6%. Bollinger Bands are 311.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Diagnostics & Research | |
| Shares Out. (M) | 48.72 |
| Shares Float (M) | 33.85 |
| % Held by Insiders | 24.06 |
| % Held by Institutions | 41.45 |
| Shares Short (K) | 323 |
| Shares Short Prior Month (K) | 369 |
| Stock Financials | |
|---|---|
| EPS | -1.190 |
| Book Value (p.s.) | 0.920 |
| Profit Margin | -26.89 |
| Operating Margin | -23.46 |
| Return on Assets (ttm) | -15.0 |
| Return on Equity (ttm) | -47.6 |
| Qtrly Rev. Growth | -31.1 |
| Gross Profit (p.s.) | 0.861 |
| Sales Per Share | 2.029 |
| EBITDA (p.s.) | -0.416 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -19.24 |
| Levered Free Cash Flow (M) | -13.79 |
| Stock Valuation | |
|---|---|
| PE Ratio | -1.82 |
| PEG Ratio | |
| Price to Book value | 2.36 |
| Price to Sales | 1.07 |
| Price to Cash Flow | -5.49 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
